secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2022-12-08T23:59:59+00:00
Accession:  0000950170-22-026236
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista terminates KVD824 Phase 2 trial over liver enzyme elevations; net loss widens to $22.3M
--------------------------------------------------------------------------------

- Phase 2 KOMPLETE trial for KVD824 terminated due to patient liver enzyme elevations; future development uncertain.
- Net loss of $22.3M ($0.90 per share) for quarter ended Oct 31, 2022 vs $19.7M ($0.80) a year ago.
- Cash, cash equivalents and marketable securities at $122.3M as of Oct 31, 2022, down from $166.2M at Apr 30.
- Phase 3 KONFIDENT trial for sebetralstat on track; data expected H2 2023, NDA filing planned H1 2024.
- Appointed Brian J. G. Pereira, M.D., as Chairman of the Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000095017022026236/0000950170-22-026236-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000095017022026236/kalv-20221208.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-026236

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer